Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 10/20 | 0.48 |
| ▸ | NOS1 | P29475 | 9/20 | 0.48 |
| ▸ | NOS3 | P29474 | 6/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 2/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 2/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | CTSV | O60911 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | STK10 | O94804 | 1/20 | 0.36 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5037007 | 0.84 | NOS2 (0.51) | NOS2NOS1NOS3CYP2C9MET | |
| SCHEMBL5036433 | 0.76 | NOS2 (0.72) | NOS2NOS1NOS3CYP2C9 | |
| SCHEMBL4295424 | 0.73 | NOS2 (0.58) | NOS2NOS1NOS3CYP2C9 | |
| SCHEMBL5037053 | 0.73 | NOS2 (0.59) | NOS2NOS1NOS3CYP2C9TLR8 | |
| SCHEMBL4666236 | 0.72 | NOS2 (0.48) | NOS2NOS1NOS3CYP2C9 | |
| SCHEMBL5042184 | 0.72 | KIT (0.42) | NOS2NOS1NOS3CYP2C9 | |
| SCHEMBL5037040 | 0.72 | NOS2 (0.57) | NOS2NOS1NOS3CYP2C9 | |
| SCHEMBL5041158 | 0.72 | NOS2 (0.67) | NOS2NOS1NOS3CYP2C9 | |
| SCHEMBL5033915 | 0.71 | NOS2 (0.56) | NOS2NOS1NOS3CYP2C9 | |
| SCHEMBL5044052 | 0.71 | NOS2 (0.42) | NOS2NOS1NOS3CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138399-B2 | 2-[2-(4-alkoxypyridin-2-yl)alkyl])-3H-imidazo[4,5-b]pyridine derivatives and 8-[2-(4-alkoxypyridin-2-yl)alkyl])-9H-purine derivatives; used to treat an acute inflammatory disease in which the activity of inducible NO-synthase is involved | ALTANA PHARMA AG (DE) | 2006-11-21 | — | — | US | disclosed |
| US-20050171125-A1 | 2-[2-(4-alkoxypyridin-2-yl)alkyl])-3H-imidazo[4,5-b]pyridine derivatives and 8-[2-(4-alkoxypyridin-2-yl)alkyl])-9H-purine derivatives; used to treat an acute inflammatory disease in which the activity of inducible NO-synthase is involved | ALTANA PHARMA AG (DE) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171125-A1 | 2-[2-(4-alkoxypyridin-2-yl)alkyl])-3H-imidazo[4,5-b]pyridine derivatives and 8-[2-(4-alkoxypyridin-2-yl)alkyl])-9H-purine derivatives; used to treat an acute inflammatory disease in which the activity of inducible NO-synthase is involved | NOS2, PNP, PTGIS | NOS2 1/4885NOS1 4/4885NOS3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.